Discussions with leaders: JNM editor-in-chief Johannes Czernin continues a series of interviews with leaders in nuclear and molecular imaging and therapy with a conversation with Joanna Fowler.
Page 1191
Solid-state detector SPECT MPI: Slomka and colleagues summarize state-of-the-art solid-state SPECT myocardial perfusion imaging technology and clinical applications, including emerging techniques for flow estimation, new protocols, potential pitfalls, and data on diagnostic and prognostic validation.
Page 1194
Training requirements for theranostics: Graham and Buatti offer preliminary advice for planning in modifying current residency training programs and education for practicing physicians to meet the demands of rapidly evolving theranostic applications in oncology.
Page 1205
Vascular calcification: Strauss and colleagues provide an educational overview of the evolving relationship of vascular calcification to major acute coronary events.
Page 1207
99mTc-NM-01 SPECT/CT PD-L1 imaging: Xing and colleagues assess safety, radiation dosimetry, uptake, and imaging of a single-domain antibody against programmed cell death ligand-1 radiolabeled site-specifically with 99mTc for SPECT in patients with non–small cell lung cancer.
Page 1213
Simplified methods for 18F-FDHT quantitation: Kramer and colleagues describe simplified methods for quantifying 18F-FDHT uptake in patients with metastatic castration-resistant prostate cancer and explore the effects of tumor perfusion on uptake metrics.
Page 1221
Additional imaging recommendations in 18F-FDG PET/CT: Alesawi and colleagues assess the frequency, determinants, and costs of recommendations for additional imaging in clinical 18F-FDG PET/CT reports.
Page 1228
18F-florbetapir PET/CT in AL amyloidosis: Ehman and colleagues use 18F-florbetapir PET/CT to detail the distribution and frequency of immunoglobulin amyloid light-chain deposits in the various organs of individuals with systemic AL amyloidosis.
Page 1234
5-Fluorouracil and epigenetic modifiers in NETs: Jin and colleagues report on an in vitro study exploring the effects of 5-fluorouracil plus the DNA methyltransferase inhibitor decitabine or the histone deacetylase inhibitor tacedinaline on neuroendocrine tumor cells.
Page 1240
18F-FES imaging of active ER mutants: Kumar and colleagues determine the effect of estrogen receptor-α gene mutations in tyrosine 537 amino acid residue within the ligand-binding domain on 18F-FES binding and in vivo tumor uptake.
Page 1247
PET/MRI in biochemical failure: Metser and colleagues assess whether the addition of multiparametric pelvic and whole-body MRI data to 18F-FCH or 68Ga-PSMA PET/CT improves detection of local tumor recurrence or nodal/distant metastases after radical prostatectomy with biochemical failure.
Page 1253
Multivariate analysis of PRRT: Aalbersberg and colleagues detail clinical and treatment parameters associated with progression-free and overall survival in patients undergoing peptide receptor radionuclide therapy for neuroendocrine neoplasms.
Page 1259
111In-pentetreotide vs. 68Ga-DOTATATE: Hope and colleagues compare the results of somatostatin-receptor PET–based and 111In-pentetreotide–based Krenning scores in selection of patients for peptide receptor radionuclide therapy.
Page 1266
PSMA uptake in salivary glands: Rupp and colleagues investigate whether the accumulation of prostate-specific membrane antigen–targeting radioligands in submandibular glands can be explained with PSMA expression levels using autoradiography and immunohistochemistry.
Page 1270
qPSMA semiautomatic software: Gafita and colleagues introduce and validate a semiautomatic software package for whole-body tumor burden assessment using 68Ga-prostate-specific membrane antigen 11 PET/CT in patients with prostate cancer.
Page 1277
Al18F-PSMA-BCH PET for prostate cancer: Liu and colleagues report on the development and preclinical evaluation of an Al18F-labeled radiotracer for PET imaging in prostate cancer and present results in newly diagnosed patients.
Page 1284
MSLN-TTC and DDR inhibitors: Wickstroem and colleagues explore the effects of blocking the DNA damage response pathway to further sensitize cancer cells and inhibit DNA repair, thereby increasing the response to mesothelin targeted 227Th conjugate α-therapy.
Page 1293
211At in thyroid cancer: Watabe and colleagues present in vitro and preclinical studies targeted at enhancing 211At solution uptake in differentiated thyroid cancer by the addition of ascorbic acid and discuss potential clinical benefits.
Page 1301
CIRPI and pathology of TCFA: Zaman and colleagues describe development and testing of the catheter-based Circumferential Intravascular Radioluminescence Photoacoustic Imaging system in detection and characterization of thin-cap fibroatheroma structure and biology in rabbit abdominal aorta.
Page 1308
Immune response monitoring with 64Cu-αCD11b: Cao and colleagues report on this tracer for longitudinal assessment by small-animal PET/CT of local and systemic immune response involving mobilization of CD11b+ myeloid cells.
Page 1317
Mesangial cell molecular imaging: Qin and colleagues demonstrate receptor-mediated binding of tilmanocept to CD206 within the kidney and provide evidence of kinetic sensitivity of this binding to renal function.
Page 1325
- © 2019 by the Society of Nuclear Medicine and Molecular Imaging.